Currency In USD
| Previous Close | 28.56 |
| Open | 25.5 |
| Day High | 28.72 |
| Day Low | 23.37 |
| 52-Week High | 74.47 |
| 52-Week Low | 14.03 |
| Volume | 93,256 |
| Average Volume | 16,906 |
| Market Cap | 19.07M |
| PE | -43.27 |
| EPS | -0.66 |
| Moving Average 50 Days | 34.03 |
| Moving Average 200 Days | 28.6 |
| Change | 0 |
Data not available
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
GlobeNewswire Inc.
Dec 17, 2025 1:00 PM GMT
Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for Graves’ disease (“GD”) and thyroid eye disease (“TED”)Yarrow Bioscience
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
GlobeNewswire Inc.
Jul 30, 2025 12:00 PM GMT
Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Baseline in F-VASI and T-VASI at 3% Concentration Co
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202
GlobeNewswire Inc.
Jul 02, 2025 11:45 AM GMT
BRIDGEWATER, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune